论文部分内容阅读
3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]-indol-1-ones(Ⅰ)were developed with the aid of protein structure-based drug design by Pfizer as the third generation of novel 5,6,7-tricyclic PARP-1 inhibitors.